You are using an outdated browser. Please upgrade your browser to improve your experience.

You are using an outdated browser.

To ensure optimal security, this website will soon be unavailable on this browser. Please upgrade your browser to allow continued use of ACP websites.

Assessment of Hepatitis B Virus (HBV) Status before Initiating Anti-Tumor Necrosis Factor (TNF) Therapy

Percentage of patients aged 18 years and older with a diagnosis of inflammatory bowel disease (IBD) who had Hepatitis B Virus (HBV) status assessed and results interpreted within one year prior to receiving a first course of anti-TNF (tumor necrosis factor) therapy.

Date Reviewed: November 4, 2018

Measure Info

MIPS 275CMS 275CQMC Core Measure
Measure Type: 
Process
Measure Steward: 
American Gastroenterological Association
Clinical Topic Area: 
Inflammatory Bowel Disease

Care Setting: 
Outpatient
Data Source: 
Registry

ACP supports MIPS measure ID# 275: “Inflammatory Bowel Disease: Assessment of Hepatitis B Virus Status before Initiating Anti-Tumor Necrosis Factor Therapy” because implementation will likely lead to measureable and meaningful improvements in clinical outcomes, the level of attribution specified in the measure (individual clinician) is appropriate, the measure addresses an intervention that is under the influence of the clinician being assessed, and the measurement results provide information that will help clinicians to improve care. While we support this measure, we note several concerns that developers should address during the next review to update the measure. First, developers do not cite current performance data and therefore, we cannot assess the opportunity for improvement. Payment and accountability programs have included this measure as an option for reporting for many years and therefore, performance data should exist to demonstrate the opportunity for improvement. Second, developers should present data on the frequency of HBV reactivation with Anti-TNF therapy to demonstrate the opportunity for improvement. Citing case reports is not sufficient to properly document the frequency of reactivation. Third, developers should revise the numerator specifications to precisely define what constitutes a “first course” of therapy. For example, “first course” could mean “first course ever” or, “first course of therapy for the most recent reactivation.” Finally, we note that the documentation requirements pose some burden on the reporting clinician. The one-year look-back window for HBV assessment requires continuity of medical records and a fairly sophisticated review of the claims data/diagnosis codes.

As part of an ongoing effort to improve user experience, we have made some updates to the Performance Measures section of ACP. Tell us what you think!